NCT03108287View on ClinicalTrials.gov

Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori

PHASE4CompletedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

April 1, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

February 28, 2015

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

RAK therapy

rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg twice-daily

DRUG

RBAK therapy

rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg, bismuth subcitrate 360mg twice-daily

All Listed Sponsors
lead

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

NCT03108287 - Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori | Biotech Hunter | Biotech Hunter